Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline

Vergote, 2010, Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N. Engl. J. Med., 363, 943, 10.1056/NEJMoa0908806

Kehoe, 2015, Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial, Lancet, 386, 249, 10.1016/S0140-6736(14)62223-6

Kang, 2015, Neoadjuvant chemotherapy for ovarian cancer: do we have enough evidence?, Lancet, 386, 223, 10.1016/S0140-6736(14)62259-5

Fagotti, 2015, Phase III SCORPION trial (ID number: NCT01461850) in epithelial cancer patients with high tumor load receiving PDS versus NACT: an interim analysis on peri-operative outcome

Onda, 2014, Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in phase III randomized trial: JCOG0602, J. Clin Oncol, 32

van Meurs, 2013, Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial, Eur. J. Cancer, 49, 3191, 10.1016/j.ejca.2013.06.013

Aletti, 2007, A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model, Gynecol. Oncol., 107, 99, 10.1016/j.ygyno.2007.05.032

Axtell, 2007, Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer, J. Clin. Oncol., 25, 384, 10.1200/JCO.2006.07.7800

Fagotti, 2013, A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer, Am. J. Obstet. Gynecol., 209, 462.e1-11, 10.1016/j.ajog.2013.07.016

Gerestein, 2011, Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer, Anticancer Res., 31, 4043

Suidan, 2014, A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer, Gynecol. Oncol., 134, 455, 10.1016/j.ygyno.2014.07.002

Thrall, 2011, Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly, Obstet. Gynecol., 118, 537, 10.1097/AOG.0b013e31822a6d56

Winter, 2007, Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study, J. Clin. Oncol., 25, 3621, 10.1200/JCO.2006.10.2517

Wright, 2011, Defining the limits of radical cytoreductive surgery for ovarian cancer, Gynecol. Oncol., 123, 467, 10.1016/j.ygyno.2011.08.027

Bohm, 2015, Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma, J. Clin. Oncol., 33, 2457, 10.1200/JCO.2014.60.5212

Fagotti, 2013, Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience, Gynecol. Oncol., 131, 341, 10.1016/j.ygyno.2013.08.005

Hynninen, 2013, A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer, Gynecol. Oncol., 131, 389, 10.1016/j.ygyno.2013.08.023

Michielsen, 2014, Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT, Eur. Radiol., 24, 889, 10.1007/s00330-013-3083-8

Kang, 2010, Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis, J. Surg. Oncol., 101, 13, 10.1002/jso.21398

Chan, 2007, Influence of the gynecologic oncologist on the survival of ovarian cancer patients, Obstet. Gynecol., 109, 1342, 10.1097/01.AOG.0000265207.27755.28

Earle, 2006, Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients, J. Natl. Cancer Inst., 98, 172, 10.1093/jnci/djj019

Goff, 2006, Ovarian cancer: patterns of surgical care across the United States, Gynecol. Oncol., 103, 383, 10.1016/j.ygyno.2006.08.010

Bristow, 2015, Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival, J. Am. Coll. Surg., 220, 940, 10.1016/j.jamcollsurg.2015.01.056

Bristow, 2009, Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes, Gynecol. Oncol., 115, 334, 10.1016/j.ygyno.2009.08.025

Cliby, 2015, Ovarian cancer in the United States: contemporary patterns of care associated with improved survival, Gynecol. Oncol., 136, 11, 10.1016/j.ygyno.2014.10.023

Vernooij, 2009, Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands, Gynecol. Oncol., 112, 455, 10.1016/j.ygyno.2008.11.011

Audisio, 2008, Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study, Crit. Rev. Oncol. Hematol., 65, 156, 10.1016/j.critrevonc.2007.11.001

Hurria, 2005, Developing a cancer-specific geriatric assessment: a feasibility study, Cancer, 104, 1998, 10.1002/cncr.21422

Rivard, 2016, Evaluation of the performance of the ACS NSQIP surgical risk calculator in gynecologic oncology patients undergoing laparotomy, Gynecol. Oncol., 141, 281, 10.1016/j.ygyno.2016.02.015

Elattar, 2011, Optimal primary surgical treatment for advanced epithelial ovarian cancer, Cochrane Database Syst. Rev., 10.1002/14651858.CD007565.pub2

Armstrong, 2006, Intraperitoneal cisplatin and paclitaxel in ovarian cancer, N. Engl. J. Med., 354, 34, 10.1056/NEJMoa052985

Buist, 2015, Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer (LapOvCa): a multicentre randomised controlled trial, ESGO19

Rutten, 2014, Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer, Cochrane Database Syst. Rev., 2, 10.1002/14651858.CD009786.pub2

Fagotti, 2016, Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome, Eur. J. Cancer, 59, 22, 10.1016/j.ejca.2016.01.017

Alberts, 1996, Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer, N. Engl. J. Med., 335, 1950, 10.1056/NEJM199612263352603

Markman, 2001, J. Clin. Oncol., 19, 1001, 10.1200/JCO.2001.19.4.1001

Thrall, 2011, Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer, Gynecol. Oncol., 123, 461, 10.1016/j.ygyno.2011.08.030

Wright, 2014, Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer, Cancer, 120, 1246, 10.1002/cncr.28508

Chang, 2013, Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis, Gynecol. Oncol., 130, 493, 10.1016/j.ygyno.2013.05.040

du Bois, 2003, A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer, J. Natl. Cancer Inst., 95, 1320, 10.1093/jnci/djg036

McGuire, 1996, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med., 334, 1, 10.1056/NEJM199601043340101

Ozols, 2003, Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study, J. Clin. Oncol., 21, 3194, 10.1200/JCO.2003.02.153

Katsumata, 2013, Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial, Lancet Oncol., 14, 1020, 10.1016/S1470-2045(13)70363-2

Oza, 2015, Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial, Lancet Oncol., 16, 928, 10.1016/S1470-2045(15)00086-8

Chan, 2016, Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer, N. Engl. J. Med., 374, 738, 10.1056/NEJMoa1505067

Pignata, 2014, Carboplatin plus paclitaxel once a week versus every 3weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol., 15, 396, 10.1016/S1470-2045(14)70049-X

Tiersten, 2009, Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009, Gynecol. Oncol., 112, 444, 10.1016/j.ygyno.2008.10.028

Mackay, 2011, Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21., Curr. Oncol., 18, 84, 10.3747/co.v18i2.725

Mackay, 2016, OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC), J. Clin. Oncol., 34, 10.1200/JCO.2016.34.18_suppl.LBA5503

Gordon, 2001, Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan, J. Clin. Oncol., 19, 3312, 10.1200/JCO.2001.19.14.3312

Dizon, 2013, The power of words: discussing decision making and prognosis, 442

Tew, 2015, Treatment of ovarian cancer in the older woman, Gynecol. Oncol., 136, 136, 10.1016/j.ygyno.2014.10.028

Forde, 2015, Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population, Gynecol. Oncol., 137, 479, 10.1016/j.ygyno.2015.03.050

Rowland, 2015, Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65years old or older, Am. J. Obstet. Gynecol., 212, e1

Kumar, 2016, Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer, Gynecol. Oncol., 140, 15, 10.1016/j.ygyno.2015.10.025